SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,670,612 | +2.4% | 390,538 | +47.6% | 0.02% | -5.3% |
| Q2 2023 | $5,539,020 | -22.8% | 264,645 | -22.1% | 0.02% | -24.0% |
| Q1 2023 | $7,172,183 | +2812520.8% | 339,592 | +3290.8% | 0.02% | +2400.0% |
| Q4 2022 | $255 | -99.9% | 10,015 | -50.2% | 0.00% | -50.0% |
| Q3 2022 | $484,000 | -88.1% | 20,121 | -90.5% | 0.00% | -86.7% |
| Q2 2022 | $4,055,000 | -34.8% | 210,744 | -25.8% | 0.02% | -16.7% |
| Q4 2021 | $6,216,000 | +148.0% | 283,954 | +67.2% | 0.02% | +28.6% |
| Q3 2020 | $2,506,000 | -5.1% | 169,792 | -4.7% | 0.01% | -17.6% |
| Q2 2020 | $2,641,000 | – | 178,192 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |